ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Qualitative Research"

  • Abstract Number: 2160 • ACR Convergence 2024

    Development of a Lupus Chatbot

    Leila Khalili1, Pooja Desai2, Maya Souvignier1, Sophie Askanase2, Lena Mamykina2 and Anca Askanase1, 1Columbia University Medical Center, New York, NY, 2CUIMC, New York, NY

    Background/Purpose: Artificial Intelligence (AI) is poised to take the world of medicine by storm. The next decade will likely bring major changes in technology use…
  • Abstract Number: 1107 • ACR Convergence 2024

    Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective

    Carine Moezinia1, Jan Nouza2, Beatrice Hornstein-Lasry2, Luai Kawar2, Asim Khan2 and Jessica Manson2, 1University College London Hospital, London, England, United Kingdom, 2University College London Hospital, London, United Kingdom

    Background/Purpose: Pyrexia of Unknown Origin (PUO) is defined as a fever above 38.3°C recorded on several occasions, that evades diagnosis for at least 3 weeks.…
  • Abstract Number: 2166 • ACR Convergence 2024

    Nominal Group Technique to Identify What Adolescents with JIA and Parents of Children with JIA Consider When Making Treatment Change Decisions

    Melissa Mannion1, Livie Timmerman2, Emily Smitherman1, Jeffrey Curtis3 and Ronan O'Beirne1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Gardendale, AL, 3The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a life-long disease that often requires escalation of therapy to achieve disease control. The goal of this project was…
  • Abstract Number: 1179 • ACR Convergence 2024

    Development of an Optimal Physiotherapy Intervention to Reduce Stiffness Following Knee Joint Replacement

    Michelle Hall1, Fiona Moffatt1, Ben Smith2, Melanie Narayanasamy3, Joanne Stocks1, Katie Sheehan4 and Catherine Sackley3, 1University of Nottingham, Nottingham, United Kingdom, 2University Hospitals of Derby and Burton NHS Foundation Trust, Derby, England, United Kingdom, 3University of Nottingham, Nottingham, England, United Kingdom, 4Queen Mary University of London, London, England, United Kingdom

    Background/Purpose: Arthrofibrosis is a complication following knee joint replacement due to excessive scar tissue formation. It leads to knee stiffness,  restricted range of movement (ROM)…
  • Abstract Number: 2171 • ACR Convergence 2024

    A Qualitative Exploration of Oral Healthcare Needs Amongst Canadian Patients with Rheumatic Diseases and Their Providers

    Chrysi Stavropoulou1, Corrie Billedeau2, Jennifer Protudjer1 and Carol Hitchon1, 1University of Manitoba, Winnipeg, MB, Canada, 2NA, Winnipeg, MB, Canada

    Background/Purpose: Patients with autoimmune rheumatic diseases (RDs) have a high prevalence of oral manifestations and/or oral side effects from immunomodulatory medications. These factors combined with…
  • Abstract Number: 1234 • ACR Convergence 2024

    Patient and Physician Preferences for Pain Relief Treatment for Moderate-to-Severe Pain Associated with Knee Osteoarthritis: A Qualitative Exploration

    Nadine Henderson1, Claud Theakston1, Sulayman Chowhury1, David Mott1, Chris Skedgel1, rita Freitas2, Stefan Ivanicius3, Gudula Petersen3, Samantha Schofield3, Angie Botto-van Bemden4, Mickaël Hiligsmann5, Ricardo larrainzar6, Deborah Marshall7, Tommi Tervonen8 and David Walsh9, 1Office of Health Economics, London, United Kingdom, 2Grünenthal GmbH, Aachen, Germany, 3Grunenthal GmbH, Aachen, Germany, 4Musculosketal Research International, Miami, FL, 5Maastricht University, Maastricht, Netherlands, 6Hospital Universitario Infanta Leonor, Madrid, Spain, 7University of Calgary, Calgary, AB, Canada, 8Kielo Research, Zug, Switzerland, 9University of Nottingham, Nottingham, United Kingdom

    Background/Purpose: Knee osteoarthritis (KOA) is a leading global cause of disability and chronic pain (Cross et al., 2014). It is well established that KOA affects…
  • Abstract Number: 1240 • ACR Convergence 2024

    Living with Antiphospholipid Antibodies: A Photovoice Exploration

    Francesca Cardwell1, Susan J. Elliott2, Paul S. Gibson3, Nancy Soliman4, Leslie Skeith4, Ann E. Clarke5 and Megan Barber5, 1University of Waterloo, Burlington, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3University of Calgary, Calgary, AB, Canada, 4University of Calgary, Calgary, ON, Canada, 5Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

    Background/Purpose: The diverse manifestations of antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPLs) exert substantial but poorly understood impacts on the lives of those affected. This…
  • Abstract Number: 1242 • ACR Convergence 2024

    Qualitative Patient Interview Study in Patients with Systemic Lupus Erythematosus to Assess Patient Perception of Fatigue and Skin-Related Symptoms

    Joseph F. Merola1, Victoria Werth2, Jiyoon C. Choi3, Brandon Becker3, Teresa Edwards4, Coburn Hobar5, Samantha Pomponi5 and Vibeke Strand6, 1UT Southwestern Medical Center, Dallas, TX, 2Hospital of the University of Pennsylvania, Philadelphia, PA, 3Bristol Myers Squibb, Princeton, 4RTI International, Research Triangle Park, NC, 5Bristol Myers Squibb, Princeton, NJ, 6Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that disproportionately impacts women of childbearing age. Although the incidence varies widely based on ethnic…
  • Abstract Number: 1245 • ACR Convergence 2024

    Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative

    Stephanie Tancer1, Basmah Al Dulaijan2 and Puja Khanna3, 1University of Michigan Department of Internal Medicine, Division of Rheumatology, Ann Arbor, MI, 2Michigan Medicine, Ann Arbor, MI, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Gout is a chronic inflammatory arthritis induced by hyperuricemia and manifested by recurrent acute flares of debilitating joint pain when left untreated. Allopurinol is…
  • Abstract Number: 1250 • ACR Convergence 2024

    Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren’s Disease

    Suzanne Arends1, Jiyoon C. Choi2, Brandon Becker2, Teresa Edwards3, Antoine Sreih4, Antonia Christodoulou4 and Vibeke Strand5, 1Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Bristol Myers Squibb, Princeton, 3RTI International, Research Triangle Park, NC, 4Bristol Myers Squibb, Princeton, NJ, 5Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA

    Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration of the endocrine glands. Globally, SjD affects between 0.01% and 0.05%…
  • Abstract Number: 0179 • ACR Convergence 2024

    Bridging the Gap: Enhancing Diversity in Lupus Clinical Trials Through Investigator and Research Staff Engagement

    Tessa Englund1, Katherine Holben1, Simone Frank2, Khadeejatul-Kubraa Lawal1, Julie Hsieh3, Christine Lee3 and Saira Sheikh1, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3U.S. Food and Drug Administration, Silver Spring, MD

    Background/Purpose: Lupus disproportionately affects diverse racial and ethnic minority populations, yet there is a significant disparity between those affected and those enrolled in clinical trials.…
  • Abstract Number: 1255 • ACR Convergence 2024

    Development and Validation of a Brief Measure of Uncertainty Among Patients with Vasculitis and Other Rheumatic Diseases

    Caleb Bolden1, Claire Cook1, Lucy Finkelstein-Fox1, Xiaoqing Fu1, Flavia Castelino1, Hyon K. Choi2, Cory Perugino1, John Stone3, Elyse Park1, Christine Yeung4, Corrie Stone-Johnson5, Stacey Ivits6, Peter Merkel7, Daniel Hall1 and Zachary Wallace8, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Lexington, MA, 3Massachusetts General Hospital , Harvard Medical School, Concord, MA, 4University of Pennsylvania, Philadelphia, 5University at Buffalo, Buffalo, NY, 6Stacey Ivits MSW RSW Counselling Services, Ontario, 7Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 8Massachusetts General Hospital, Newton, MA

    Background/Purpose: Patients with rheumatic diseases face illness-related uncertainty managing ambiguous and unpredictable symptoms. Such uncertainty is associated with decreased emotional and physical well-being (Wallace et…
  • Abstract Number: 0187 • ACR Convergence 2023

    Advancing Health Equity with Lupus Stakeholders to Close Care Gaps and Disparities

    Shalvi Parikh1, Monica Messina1, Shivani Garg1, Sancia Ferguson2, Edmond Ramly3, Andrea Gilmore-Bykovskyi4, Katrina Phelps5 and Christie M. Bartels6, 1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2University of Wisconsin, Madison, WI, 3Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, 4University of Wisconsin School of Medicine and Public Health, Madison, WI, 5School of Nursing, University of Wisconsin-Madison, Madison, WI, 6University of Wisconsin, School of Medicine and Public Health, Madison, WI

    Background/Purpose: Systemic lupus erythematosus (SLE) care and outcomes are associated with significant racial and socioeconomic disparities in the US, particularly among young Black and Hispanic/Latina…
  • Abstract Number: 1432 • ACR Convergence 2023

    Experiences and Perspectives of Patients with Psoriatic Arthritis Participating in a Randomized Controlled Trial of Dietary Interventions

    Lihi Eder1, Sanjana Tarannum2, Kathleen Bush3, Sarah Cohen4, Charlene Compher4, Helen Emanoilidis2, Sarah Gillespie3, Dafna Gladman5, Vinod Chandran6, Jose Scher7 and Alexis R Ogdie4, 1Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 2Women's College Hospital, Toronto, ON, Canada, 3Division of Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, PA, 4University of Pennsylvania, Philadelphia, PA, 5Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 6Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, 7New York University School of Medicine, New York, NY

    Background/Purpose: Dietary Interventions in psoriatic arthritis (DIPSA) is a randomized controlled trial (RCT) assessing the efficacy of dietary modifications in patients with psoriatic arthritis (PsA).…
  • Abstract Number: 0327 • ACR Convergence 2023

    Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre

    Saadia Sasha Ali1, Karafotias Ioasaf2, Bechman Katie3, Andrew Rutherford4, Sophia Steer3 and Elena Nikiphorou3, 1King's College Hospital, Epsom, United Kingdom, 2King's College Hospital, London, United Kingdom, 3King's College London, London, United Kingdom, 4King's College Hospital, London, United Kingdom

    Background/Purpose: The 2021 EULAR guidelines on self-management have made recommendations (rec) to aid with the implementation of self-management strategies in inflammatory arthritis (IA) (1). Their…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology